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OBJECTIVES: Standard practice to maintain remission in ulcer-
ative colitis (UC) consists of daily mesalazine therapy. However,
frequency of dosing can lead to poor adherence and increased
failure rates. The PODIUM (PentasaTM Once Daily In UC
Maintenance) randomized control trial showed 2g once daily
(OD) to be superior to twice daily (BD) dosing for maintaining
remission. As maintenance therapy for UC evolves to once daily
regimens, we sought to establish whether this new treatment
paradigm is cost-effective by considering costs in relation to
outcomes. METHODS: An economic evaluation was conducted
to compare costs and outcomes from the PODIUM trial. Cost
data was obtained from published sources. The main outcome
considered was quality-adjusted life-years (QALYs) based on
health state utilities derived from the primary outcome measure,
remission without relapse at 12 months, deﬁned by a UCDAI
score <1. The probability of relapse (deﬁned by UCDAI > 2, or
UCDAI = 2 with treatment adjusted) for OD and BD dosing were
based on results from the PODIUM study. The economic evalu-
ation consisted of two health states: 1) remission, and 2) active
UC. Model duration was one year. Active UC was assessed and
treated according to British Society of Gastroenterology guide-
lines. RESULTS: Annual average treatment costs for OD and
BD were £654 (95% CI: £536–£759) and £747 (£620–£860),
respectively with an average per person savings of £93. There
was no difference in annual costs of mesalazine with OD and BD.
Average annual costs of ancillary care for relapse for OD and BD
were £307 (£241–£383) and £396 (£320–£483), respectively.
Based on the cost savings identiﬁed with OD this would represent
an annual savings of £46,500 in a District General Hospital
serving a Primary Care population of 500 UC patients. Treat-
ment with OD 2g mesalazine resulted in an incremental QALY
improvement of 0.004, indicating it was the dominant treatment
option (ie. improved outcomes and cost-saving). Variations in
parameter estimates in the sensitivity analysis indicated that
mesalazine had >0.94 probability of being cost-effective com-
pared to BD based on accepted willingness to pay thresholds
within the UK National Health Service. CONCLUSIONS: Once
daily 2g mesalazine for maintaining remission in UC is cost-
saving compared with 1g BD. Cost-savings with OD 2g were
achieved by differences in ancillary care between the two treat-
ments attributed to higher failure rates observed with 1g BD.
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OBJECTIVES: To provide a cost-efﬁcacy (CE) analysis of
achieving remission in Crohn’s disease (CD) patients following
treatment with inﬂiximab or certolizumab pegol from a payer
perspective. METHODS: An Excel-based CE model was devel-
oped to estimate cost per successful remission of CD using
published data for inﬂiximab and certolizumab pegol. Dosing
information was obtained from the product labels. Drug costs
were obtained from First Databank data for April 2008 whole-
sale acquisition cost (WAC). The cost for one 100 mg vial of
inﬂiximab was $604, and for one 200 mg syringe of certoli-
zumab pegol was $658. The medical cost for inﬂiximab infusions
was estimated to be $237 per infusion based on the Medicare
2005 infusion schedule. The medical cost per certolizumab pegol
administration was estimated at $37 based on HCPCs code
99212, for an ofﬁce outpatient visit. The cost of adverse events
was not included in the model. Remission rates, deﬁned as the
percentage of patients achieving a Crohn’s Disease Activity Index
(CDAI) score of less than or equal to 150, were used as the
efﬁcacy measure. A remission rate of 39.0% was reported at
week 30 in the ACCENT I trial for inﬂiximab. A remission rate
of 29.0% was reported at week 26 in the PRECISE I trial for
certolizumab pegol. The time horizon on the study was 30 weeks,
as long-term effectiveness data are not yet available for certoli-
zumab pegol. RESULTS: The average cost per successfully
treated patient, those achieving remission based on the CDAI
score was $33,922 for inﬂiximab and $37,324 for certolizumab
pegol. CONCLUSIONS: Based on this model, the cost of a
successfully treated patient is higher for certolizumab pegol than
inﬂiximab, suggesting that inﬂiximab is more cost effective than
certolizumab pegol for treatment of CD. Direct comparative
trials and real world data are needed to conﬁrm these ﬁndings.
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OBJECTIVES: To estimate the cost-effectiveness of available
treatments for CHB in HBeAg-negative and HBeAg-positive
patients in Spain. METHODS: A Markov model was used to
project, over the next 30 years, theHBV-related complications and
future costs of consecutive cohorts of CHB patients in Spain
treated with adefovir, entecavir, lamivudine, pegylated interferon,
telvibudine and tenofovir. A second line combination therapy
(lamivudine+adefovir) was assigned for patients resistant to any
ﬁrst-line oral antiviral option, whilst patients not responding to
oral treatments where assumed to discontinue therapy and
experience the risk of disease complications, as described by the
natural history of CHB. Patients not responding to pegylated
interferon were assumed to start an oral treatment—tenofovir or
entecavir- with corresponding costs and effects. The probabilities
of disease progression were based on HBV-DNA levels for each
treatment option in the model and were obtained from data
published in the literature. Disease and complications costs were
based on the health care payer perspective at a local level (the
Spanish National Health System). An annual 3% discount rate
was applied to future costs and outcomes (quality adjusted life
years—QALY). RESULTS: The higher rate of patients with
undetectable HBV-DNA with tenofovir translated to its higher
effectiveness in terms of QALY, followed by pegylated inter-
feron, entecavir, telbivudine, lamivudine and adefovir in HBeAg-
positive patients and pegylated interferon, entecavir, telbivudine,
adefovir and lamivudine in HBeAg-negative patients. Tenofovir
presented higher effectiveness and lower costs than entecavir and
telbivudine in HBeAg-negative patients (besides pegylated inter-
feron in HBeAg-positive patients), and cost-effectiveness ratios
with respect to the rest of therapies far below the common
reference efﬁciency threshold of €30,000 per QALY in Spain.
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